| Dr Vivekanand Singh, MD | |
|
2401 Gillham Rd, Children's Mercy Hospital- Pathology, Kansas City, MO 64108-4619 | |
| (816) 234-3234 | |
| Not Available |
| Full Name | Dr Vivekanand Singh |
|---|---|
| Gender | Male |
| Speciality | Pathology - Pediatric Pathology |
| Location | 2401 Gillham Rd, Kansas City, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326006305 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 35-08-2510-S (Ohio) | Primary |
| 207ZP0213X | Pathology - Pediatric Pathology | 2004009613 (Missouri) | Primary |
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
Kindred Healthcare, Inc. today announced that it intends to undertake a refinancing of its existing secured indebtedness. The proposed refinancing would extend the maturity profile of the Company's long-term debt, increase total availability under the Company's secured facilities, improve pricing and provide additional covenant flexibility.
The National Cancer Institute has awarded a three-year grant totaling $2,168,535 to Professor Yijun Ruan, Ph.D., of The Jackson Laboratory for Genomic Medicine, for his research into the role of noncoding RNAs in cancer and other diseases.
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that the Medical Training and Testing Center in Rouen will use its R-One robot for future training.
Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vivekanand Singh, MD 2401 Gillham Rd, Children's Mercy Hospital- Pathology, Kansas City, MO 64108-4619 Ph: (816) 234-3234 | Dr Vivekanand Singh, MD 2401 Gillham Rd, Children's Mercy Hospital- Pathology, Kansas City, MO 64108-4619 Ph: (816) 234-3234 |
News Archive
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
Kindred Healthcare, Inc. today announced that it intends to undertake a refinancing of its existing secured indebtedness. The proposed refinancing would extend the maturity profile of the Company's long-term debt, increase total availability under the Company's secured facilities, improve pricing and provide additional covenant flexibility.
The National Cancer Institute has awarded a three-year grant totaling $2,168,535 to Professor Yijun Ruan, Ph.D., of The Jackson Laboratory for Genomic Medicine, for his research into the role of noncoding RNAs in cancer and other diseases.
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that the Medical Training and Testing Center in Rouen will use its R-One robot for future training.
Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.
› Verified 2 days ago
Dr. Linda D Cooley, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2401 Gillham Rd, Cytogenetics, Kansas City, MO 64108 Phone: 816-234-1201 Fax: 816-802-1492 | |
Dr. Alexey Glazyrin, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-0577 | |
Marjorie L Zucker, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 4401 Wornall, Kansas City, MO 64111 Phone: 816-932-3335 Fax: 816-932-3822 | |
Dr. Lei Shao, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 2401 Gillham Rd, Pathology Department, Kansas City, MO 64108 Phone: 816-234-3234 Fax: 816-802-1492 | |
Dr. Eugenio Miguel Taboada-arana, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2401 Gillham Rd, Pathology Department, Kansas City, MO 64108 Phone: 816-234-3234 Fax: 816-802-1492 | |
Dr. Marius Calin Tarau, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 950 E 21st St, Kansas City, MO 64108 Phone: 816-881-6609 Fax: 816-881-6616 | |
Mrs. Kamani M Lankachandra, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-0550 |